Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis

Launched by ASSIUT UNIVERSITY · Jan 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of Gentamicin and Dexamethasone, two medications that may help patients with bronchiectasis who are experiencing a sudden worsening of their condition, known as an acute exacerbation. The trial is specifically looking at how well these medications work when given directly into the lungs of patients who are on a ventilator in a respiratory intensive care unit. By comparing this method to standard treatments, researchers hope to find out if it is a safer and more effective option.

To be eligible for this trial, participants must be at least 18 years old and diagnosed with bronchiectasis, which is a condition that affects the lungs and causes breathing problems. They should also be experiencing an acute exacerbation that requires antibiotic treatment in the hospital. However, individuals with certain conditions, like active tuberculosis or specific types of allergies related to the lungs, cannot participate. If eligible, participants can expect to receive either the new treatment or conventional care, and their health will be closely monitored throughout the study. This research aims to improve treatment options for patients with bronchiectasis, especially those in critical care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with bronchiectasis confirmed by high-resolution CT chest(HRCT)
• • patients with acute exacerbation of bronchiectasis who need antibiotic treatment at the hospital due to exacerbation
• • mechanically ventilated patients in the respiratory ICU
• • Age more than or equal to 18 years
• Exclusion Criteria:
• • patients with active pulmonary tuberculosis
• • patients with allergic bronchopulmonary aspergillosis
• • patients who underwent interventional bronchoscopy for hemoptysis
• • age less than 18 years